Table 1.
| Study population (n = 54) | |
|---|---|
| Mean/median/number | |
| Age, years | 59 ± 10 |
| Female, n (%) | 7 (13) |
| Body mass index, kg/m2 | 27 ± 3 |
| Family history for AMI, n (%) | 12 (22) |
| Smoking status, n (%) | 25 (46) |
| Hypertension, n (%) | 44 (81) |
| Hyperlipidemia, n (%) | 36 (67) |
| Diabetes mellitus, n (%) | 5 (9) |
| Pain-to-balloon time, min | 261 (129–759) |
| Anterior STEMI, n (%) | 17 (32) |
| Culprit lesion, n (%) | |
| LAD | 16 (30) |
| LCX | 10 (18) |
| RCA | 28 (52) |
| Vessel disease, n (%) | |
| 1 | 24 (44) |
| 2 | 23 (43) |
| 3 | 7 (13) |
| Creatinine, mg/dL | 0.98 ± 0.15 |
| eGFR, mL/min/1.73 m2 | 83 ± 15 |
| NT-proBNP, ng/L | 219 (119–412) |
| MR-proANP, pmol/L | 88 (68–128) |
| MR-proADM, nmol/L | 0.7 ± 0.2 |
| PWV, m/sec | 7.2 ± 2.0 |
AMI = acute myocardial infarction; STEMI = ST-segment elevation myocardial infarction; LAD = left anterior descending artery; LCX = left circumflex artery; RCA = right coronary artery; eGFR = estimated glomerular filtration rate; NT-proBNP = N-terminal pro–B-type natriuretic peptide; MR-proANP = mid-regional pro–A-type natriuretic peptide; MR-proADM = mid-regional proadrenomedullin; PWV = pulse wave velocity.